Background: The B-type natriuretic peptides (BNP) and the amino-terminal probrain natriuretic peptide (NTproBNP) are good markers of prognosis and diagnosis in chronic heart failure (HF). It is unclear, however, whether differences in their biological characteristics modify their clinical correlates and prognostic performance in HF. This work aimed to provide a direct comparison of the prognostic value of BNP and NTproBNP in patients with chronic and stable HF. Methods: We measured BNP and NT-proBNP at baseline in 3916 patients enrolled in the Valsartan Heart Failure Trial. To identify the variables associated with both peptides, we conducted simple and multivariable linear regression analyses. We used Cox multivariable regression models to evaluate the independent prognostic value for all-cause mortality, mortality and morbidity, and hospitalization for HF. Prognostic performance was assessed by pairwise comparisons of the area under the curve of receiver-operator characteristic curves.
Brain natriuretic peptide (BNP) and the amino-terminal fragment of BNP (pro-hormone NT-proBNP) are secreted in equimolar amounts in response to mechanical or neurohormonal stimulation. Both peptides are reliably measured in clinical practice. Whereas BNP is a natriuretic and diuretic hormone, the biological role of NTproBNP, if any, is not well understood at present. These peptides also differ with regard to their biological halflife, in vitro stability, and mechanisms involved in their clearance (5 ) . However, there is no compelling evidence in favor of either peptide in terms of indicators of clinical severity (6 -8 ) , screening for left ventricular (LV) dysfunction in the general population (9 ) , diagnosis (10 -13 ), or prognosis (8, 14, 15 ) . In particular, a study in a large and representative population of patients with chronic HF is required to examine and compare the prognostic value of BNP and NT-proBNP in a setting that would allow sufficient statistical power to examine subgroups of patients according to their clinical characteristics.
In the Valsartan Heart Failure (Val-HeFT) trial, blood samples were collected at the time of entry into the study in a large population of patients with chronic and symptomatic HF, yielding one of the largest plasma banks collected for this disease. The clinical utility of several neurohormones, including BNP, has already been evaluated in this trial (16 -19 ) . In this study, we carried out a direct comparison of the 2 natriuretic peptides in this large population in relation to the severity of the disease and clinical outcome.
Materials and Methods study design and patients
Val-HeFT was a randomized, placebo-controlled, doubleblind, parallel-arm multicenter trial. A total of 5010 patients with stable, symptomatic HF, who were on prescribed HF therapy and who had LV ejection fraction (LVEF) of Ͻ40% and LV diameter in diastole adjusted for body surface area (LVIDd/BSA) of Ն2.9 cm/m 2 , were enrolled in the study. Results of the main trial have been presented in detail previously (20 ) .
measurement of natriuretic peptide concentrations
Blood samples were collected at study entry by venipuncture in evacuated plastic tubes containing EDTA dipotassium salt. Blood samples were centrifuged at 3500g for 10 min at 4°C immediately after collection, and plasma samples were stored at Ϫ70°C. BNP (IRMA Shionogi) and NT-proBNP (ECLIA Elecsys 2010 analyzer, Roche Diagnostics) were measured by commercially available assays in plasma samples never thawed before. Norepinephrine, plasma renin activity, and C-reactive protein were determined, as previously described (17, 19 ) . The intra-assay CVs were 2.9% and 3.9% for NT-proBNP and BNP, respectively. Corresponding interassay CVs were 3.9% and 4.7%. In 81 age-matched, healthy volunteers, the 95th percentile of concentration was 121 and 76 ng/L, for NT-proBNP and BNP, respectively.
statistical methods
We performed all statistical analyses on patients with both NT-proBNP and BNP measured at baseline (n ϭ 3916). We compared concentrations of NT-proBNP or BNP according to clinical characteristics by means of the Wilcoxon rank-sum test as the normality of the distribution was not satisfied. We assessed the correlation between baseline concentrations of BNP and NT-proBNP with the Pearson's correlation coefficient test.
Simple linear regression analyses were carried out to evaluate the relationship between baseline concentrations of BNP or NT-proBNP (expressed as log-transformed data) and clinical characteristics as continuous variables when appropriated. The assumptions underlying the linear regression models, such as linearity, normality, and homoscedasticity, were satisfied for all the independent continuous variables, except for creatinine and bilirubin, which were transformed on a logarithmic scale.
Multivariable linear regression analyses were carried out to determine the variables independently associated with NT-proBNP or BNP, expressed as continuous logtransformed concentrations. In the final models, only variables statistically significant at the univariate analysis (P Ͻ0.05) were included. ␤ regression coefficients and their significance from multiple linear regression analysis are reported.
The relationship between NT-proBNP or BNP and these variables was also explored by dividing them into quartiles and assessing differences by means of the Kruskal-Wallis test.
Cox multivariable regression models were used to evaluate the independent prognostic value of baseline NT-proBNP and BNP (entered as categorical variables below and above the median concentration) on all-cause mortality, on mortality and morbidity (M&M), and on hospitalization for HF alone. Mean follow-up time was 23 months. The model included all the demographic, clinical, and echocardiographic variables, considered as categorical, that had a significant univariate relationship with outcome. To check for possible biases resulting from the arbitrary choice of median concentration, we also carried out the same Cox multivariate analysis with continuous variables where appropriate. We checked the assumption of proportional hazard by means of the log[-log(survival)] plot and by the time-dependent covariate test. Also, we used the martingale residuals plot to evaluate whether a specific time-independent continuous covariate might be entered directly into the model, or if a transformation was necessary. To ease the interpretability of these results, hazard ratios have been computed for intervals of 50 ng/L of BNP and 500 ng/L of NT-proBNP.
To assess the incremental prognostic value of NTproBNP or BNP with respect to clinical variables, we evaluated a separate addition of NT-proBNP or BNP to a model based on demographic, clinical, and echocardiographic variables with the likelihood-ratio test with 1 degree of freedom.
To compare the predictive value of BNP and NTproBNP, ROC curves were generated for the main outcomes. Exploratory analyses were also carried out to compare the prognostic value of both natriuretic peptides for the 2 main adjudicated causes of death, sudden death from cardiac causes and death because of pump failure (20 ) . Pairwise comparisons of the areas under the curve (AUC) were conducted, following the procedure of Hanley and McNeil (21 ) .
All endpoints were adjudicated by an independent Endpoint Committee, blind to study treatment. All tests were made at a 2-sided, 5% significance level. Statistical 
Results baseline concentrations of nt-probnp and bnp and association with clinical variables
The median (25th-75th percentiles) concentration of NTproBNP at baseline was 895 (375-1985) ng/L (n ϭ 3916). Corresponding values for BNP were 99 ng/L (41-242). Pearson's coefficient of correlation between baseline concentrations of NT-proBNP and BNP was 0.77 (P Ͻ0.0001).
Plasma concentrations of NT-proBNP and BNP according to baseline clinical characteristics are presented in Table 1 . NT-proBNP and BNP were significantly higher in older patients, in those with more symptomatic HF, more dilated LV, and more severe LV dysfunction, lower body mass index (BMI), lower sitting arterial blood pressure, HF of ischemic etiology, or with atrial fibrillation at study entry. The concentration of both peptides was also higher in patients with increased laboratory markers (creatinine and bilirubin) and neurohormones (plasma renin activity, norepinephrine, and C-reactive protein). There were no relevant differences between the univariate clinical correlates of NT-proBNP or BNP, except for beta-blocker use, sitting heart rate, and plasma aldosterone concentration (all nonsignificant for BNP).
Baseline log-transformed NT-proBNP or BNP concentrations correlated with age, LVEF, and LVIDd with r 2 ranging from 0.02 to 0.12 (P Ͻ0.0001, variables as continuous data). Fig. 1 compares the relationship between median NT-proBNP or BNP and these variables, categorized by quartiles. The trend was similar for both natriuretic peptides.
The strongest continuous relationship was found between log-transformed estimated glomerular filtration rate (eGFR) and NT-proBNP (Pearson's coefficient of correlation Ϫ0.34, P Ͻ0.0001) or BNP (Ϫ0.21, P Ͻ0.0001). The relationship between median concentrations of NTproBNP or BNP and eGFR showed a steeper increase of NT-proBNP compared with BNP in patients with reduced renal function (Fig. 2) . However, the number of patients with eGFR Ͻ30 mL/min/m 2 was limited in this study (n ϭ 59, 1.5% of the population).
The clinical variables that were independently associated with baseline concentrations of BNP or NT-proBNP (expressed as log-transformed data) were largely common to both peptides, with the exception of the use of angiotensin-converting enzyme (ACE) inhibitors and beta-blockers (Table 2) . Whereas NT-proBNP was independently associated with ACE inhibitors (positive relation) and beta-blockers (negative relation), no such associations were found with BNP. The factors with the strongest association were age, ischemic etiology, presence of atrial fibrillation, LV ejection fraction, and internal diameter. Differences of median concentrations among quartiles evaluated were evaluated by the Kruskal-Wallis test and were significant for age, LVEF, and LVIDd for both peptides (all with P Ͻ0.00001). Vertical scale is different for NT-proBNP (black bars) and BNP (white bars). The number of patients in each category is shown above bars.
prognostic value of bnp and nt-probnp
The adjusted hazard ratios for death, M&M, or hospitalization for HF according to baseline deciles of NT-proBNP and BNP are presented in Fig. 3 . There was a similar progression in the probability of death with increasing plasma concentration of NT-proBNP or BNP, with hazard ratios in the tenth decile of 4.02 (2.63-6.11) and 4.02 The independent prognostic values of baseline BNP or NT-proBNP were tested separately in Cox multivariable models that included the demographic, clinical, and echocardiographic variables with a statistically significant association with outcome at univariate analysis (P Ͻ0.05). First, the natriuretic peptides and the other covariates were entered as categorical variables, dichotomized above or below (SD) the median value. In these models, NTproBNP was the first predictor of outcome with hazard ratios (95% CI) of 2.07 (1.76 -2.46) for mortality, 2.20 (1.92-2.51) for M&M, and of 2.66 (2.19 -3.22) for hospitalization for HF (Fig. 4) . Similarly, BNP resulted as the strongest independent predictor of mortality (1. . When the natriuretic peptides and appropriate covariates were considered as continuous variables, their prognostic value was consistent with the analysis based on median cutoff values. For instance, an increment of 500 ng/L of baseline NT-proBNP concentration corresponded to an increase of risk of 3.8% for mortality (P Ͻ0.0001), whereas an increment of 50 ng/L of baseline BNP concentration corresponded to an increase of risk of 5.7% (P Ͻ0.0001). Similarly, increases of risk for M&M were 3.5% and 5.4%, and 3.0% and 5.7% for hospitalization for HF, respectively (P Ͻ0.0001 for all). Finally, the likelihood-ratio test showed that BNP or NT-proBNP provided significant incremental prognostic value for the prediction of all-cause mortality, M&M, and hospitalization for HF (all with P Ͻ0.0001) compared with a model based on demographic, echocardiographic, and clinical variables.
The predictive value of NT-proBNP and BNP were compared by means of ROC curves ( Table 3) When patients were divided into clinical subgroups, NT-proBNP retained a statistical superiority over BNP in males (P ϭ 0.018 for all-cause mortality; P ϭ 0.044 for hospitalization for HF, Table 4), in patients over 70 years (P Ͻ0.0001 for all-cause mortality; P ϭ 0.023 for hospitalization for HF), or in patients with eGFR comprised between 30 and 59 mL/min/1.73 m 2 (P ϭ 0.017 for all-cause mortality; P ϭ 0.036 for hospitalization for HF). BNP and NT-proBNP performed however similarly in females, in patients Ͻ70 years, in patients with eGFR 60 -89 mL/min/1.73 m 2, in patients with or without diabetes, and in 3 classes of BMI index (Table 4) .
Discussion
Our findings indicate that the hormone BNP and the inactive amino terminal fragment NT-proBNP exhibited parallel changes with age, LVEF, and diameter in patients with chronic and symptomatic HF. These peptides were the first independent predictors of outcome after adjustment for major confounding baseline clinical characteristics. However, a head-to-head comparison of their prognostic value showed that NT-proBNP performed slightly better than BNP in predicting outcome, in particular for death from pump failure and hospitalizations for HF. These results were obtained in a large and relatively heterogeneous population of well-characterized patients enrolled in a multicenter international clinical trial. They extend the results of several previous studies performed on smaller cohorts of patients, and often in single centers (7, (11) (12) (13) 15 ) . The biological relevance of the present observations will have to be confirmed in different clinical and/or analytical settings.
relationships between nt-probnp, bnp, and clinical severity
In this study we investigated the association of various demographic, clinical, and echocardiographic variables and baseline concentrations of natriuretic peptides with univariate and multivariable models. We concluded that the set of variables associated with plasma concentrations of NT-proBNP or BNP was essentially the same, with the exception of the use of ACE inhibitors and beta-blockers. The reason for this difference is unknown at present; however, recent studies have shown that the introduction of a beta-blocker (metoprolol) in patients with mild and stable HF raised the concentration of both C-terminal and N-terminal natriuretic peptides (22) (23) . The strongest Fig. 4 . Prognostic models for all-cause mortality, M&M, and hospitalization for HF based on Cox proportional hazard regression.
Analysis adjusted for baseline NT-proBNP or BNP and the demographic, clinical, and echocardiographic variables with a significant univariate relationship with outcome (P Ͻ0.05). Data presented as hazard ratio and 95% CIs in decreasing order of 2 . Table 3 . Comparison of the prognostic performance of NT-proBNP and BNP for predicting outcome in patients with chronic heart failure. Clinical Chemistry 52, No. 8, 2006 associations were found with age, ischemic etiology of HF, presence of atrial fibrillation, LVEF, and internal diameter, as previously described (24 -26 ) . Our data also concur with the conclusion of a comparative study performed in a large cohort of patients with stable ischemic heart disease, where LVEF, age, and renal function were the most powerful independent predictors of BNP and NT-proBNP (8 ) .
Among the continuous variables, the strongest association was found with renal function. Median concentrations of the natriuretic peptides increased progressively with renal dysfunction estimated as eGFR and categorized according to the classification of the National Kidney Foundation. This trend has been observed in patients presenting in emergency departments for dyspnea (27 ) . Decreased clearance from the kidney has been put forward to explain increased BNP in patients with HF (28 ) . Although the mechanisms of elimination of these 2 peptides might differ (BNP is mainly cleared by neutral endopeptidases and specific receptors, whereas renal excretion is currently regarded as the main clearance mechanism for NT-proBNP (5 ), the increase of both peptides with lower eGFR suggests that the susceptibility of NTproBNP concentrations to renal dysfunction was not, apparently, greater than that of BNP. We must remember, however, that the number of patients with severely compromised renal function (eGFR Ͻ30 mL/min/1.73 m 2 ) was limited in our study population, so this conclusion does not apply in such patients. This extends to previous observations of patients with myocardial infarction and compensated renal dysfunction (7 ) and confirms recent studies that showed similar renal extraction of the 2 peptides in healthy volunteers and in patients with essential arterial hypertension (29, 30 ) .
prognostic value of nt-probnp and bnp in heart failure Brain natriuretic peptides (BNP and NT-proBNP) are strong markers of outcome in chronic HF (2, 17 ) . The present analysis attests to their superiority compared with other variables, but also confirms the strength of several clinical variables (older age, diabetes, and lower LVEF) that have been powerful and independent predictors of mortality and morbidity in a large and contemporary population of patients with HF (31 ) . Few studies have directly compared the prognostic value of the 2 brain natriuretic peptides in patients with heart disease. Some have concluded that they are substantially equivalent (14, 15, 32 ) . In patients with stable ischemic heart disease, Richards et al. (8 ) recently showed that both peptides independently predicted a composite clinical endpoint (1-year all-cause mortality or admission with HF) with almost overlapping, event-free survival curves. There are however some exceptions: BNP (but not NT-proANP or NT-proBNP) independently predicted sudden death in 382 patients with chronic HF (33 ), whereas NT-proBNP (but not BNP) predicted symptom-free survival and postoperative outcome in patients with severe aortic stenosis (34 ) . Differences have also been observed in acute settings, for instance in response to short term exercise (35 ) or after intravenous infusion of Levosimendan (36 ) . In the present study, NT-proBNP performed better than BNP to predict death from pump failure and hospitalization for HF (P ϭ 0.0003 and 0.0143 by univariate pairwise comparison, respectively). When patients were divided into clinical subgroups, NT-proBNP retained a statistical superiority over BNP in males, in patients over 70 years, or with eGFR ranging from 30 to 59 mL/min/1.73 m 2 . In univariate analysis, BNP and NT-proBNP performed similarly in females, in patients Ͻ70 years, or in patients with eGFR Ͼ60 mL/min/1.73 m 2 . In addition, the prognostic value of BNP and NT-proBNP was similar in patients with or without diabetes and in different classes of BMI (lean, overweight, or obese). Several factors might, in principle, explain these differences. First, the longer estimated biological half-life of NT-proBNP compared with BNP (70 min vs ϳ20 min) (37, 38 ) renders the former less prone to short-term fluctuations that may confound the prognosis. This difference is corroborated by the relatively smaller intraindividual biological variation of NTproBNP observed in patients with HF (39 ) . In the context of a large multicenter trial, preanalytical deviations from the protocol during blood collection, plasma processing, and storage would also have a greater detrimental impact on BNP compared with NT-proBNP. Second, differences in the analytical performance of the methods used to measure BNP and NT-proBNP could influence their respective prognostic value, although the impact of assay imprecision on the performance of cardiac biomarkers for diagnosis seems not to be critical (40 ) . The IRMA used in the present study to measure BNP showed slightly higher analytical variability than the automated method for NT-proBNP; this could further reduce the prognostic performance of BNP. It is important to note that immunoreactive moiety detected by any given immunoassay depends on the combined influence of circulating forms of NT-proBNP and BNP, the degree and rate at which they are degraded from amino and/or C-terminals, and (most importantly) the epitope(s) to which polyclonal or monoclonal antibodies have been raised (41 ) . Indeed, recent studies demonstrated that the clinical results (including the reference range and decisional cutoff values) of BNP and NT-proBNP assays are method-dependent (42 ) . For these reasons, the analytical performance and clinical accuracy of any single immunoassay should be assessed in each laboratory. Third, it cannot be excluded that different relationships between NT-proBNP or BNP and some clinical characteristics not considered in the present analysis might explain our data. Finally, the large number of patients considered in our study (3916) might have revealed subtle differences in the prognostic performance of the 2 peptides not detectable in smaller populations.
The relatively modest prognostic accuracy of BNP and NT-proBNP in the present study (AUCs ranging from 0.66 to 0.75, sensitivity and specificity ranging from 0.590 to 0.696) might result from the fact that our population included only patients with stable, chronic, and symptomatic mild-to-moderate HF, with LV systolic dysfunction (LVEF Ͻ40%). Effective neurohormone suppression with background therapy might also have limited the prognostic performance of these markers.
In conclusion, we report a small, but statistically significant difference in the predictive value of 2 related natriuretic peptides in a well-characterized and large population of patients with chronic and symptomatic HF.
